All posts by student

Neuroscience Archives – Neuroscience News

Neuroscience research articles are provided.

What is neuroscience? Neuroscience is the scientific study of nervous systems. Neuroscience can involve research from many branches of science including those involving neurology, brain science, neurobiology, psychology, computer science, artificial intelligence, statistics, prosthetics, neuroimaging, engineering, medicine, physics, mathematics, pharmacology, electrophysiology, biology, robotics and technology.

More:
Neuroscience Archives - Neuroscience News

Frontiers in Neuroscience

The specialty sections of Frontiers in Neuroscience welcome submission of the following article types: Book Review, Case Report, Clinical Trial, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Protocols, Review, Specialty Grand Challenge, Systematic Review, Technology Report, Brief Research Report, Conceptual Analysis, Clinical Study Protocol, Policy and Practice Reviews, Code, Curriculum, Instruction, and Pedagogy, CPC, Focused Review and Frontiers Commentary.

When submitting a manuscript to Frontiers in Neuroscience, authors must submit the material directly to one of the specialty sections. Manuscripts are peer-reviewed by the Associate and Review Editors of the respective specialty section.

Articles published in the specialty sections above will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in the Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Neuroscience.

See the rest here:
Frontiers in Neuroscience

Neuroscience | NIH Intramural Research Program

View Principal Investigators in Neuroscience

Many people consider the human brain to be the last frontier of biomedical research. To understand how it functions both normally and in disease, we need the combined efforts of talented researchers from a broad spectrum of the biological, behavioral and physical sciences.

Neuroscience has a long and rich history at the NIH, which dates back to the establishment of the National Institute of Mental Health in 1949 and the National Institute of Neurological Disorders and Stroke in 1950. As one of the largest and most diverse programs of its kind in the world, neuroscience research in the Intramural Research Program (IRP) encompasses 200 Principal Investigators, 650 postdoctoral fellows, and 100 graduate students conducting basic, behavioral, translational, and clinical research in over 150 laboratories at 12 NIH Institutes and Centers.

IRP research covers such varied areas as the biology of the neuron; biophysics of ion channels and receptors; neurodegeneration, neural development and plasticity; behavioral neuroscience; as well as clinical programs on neurodegenerative disorders, stroke, schizophrenia, mood and anxiety disorders, autism, therapies for substance abuse, and treatment of chronic pain.

In recent years, IRP researchers have:

To learn more about the IRP researchers who are affiliated with our Neuroscience program, please visit the Neuroscience@NIH site.

Excerpt from:
Neuroscience | NIH Intramural Research Program

Neuroscience – College of Arts and Sciences – Santa Clara …

A Bachelor of Science degree in neuroscience at SCU will provide students with the scientific foundation needed to understand the nervous system at many levels, from the molecular level to patient symptomatology. Students will examine the biological and psychological underpinnings of the nervous system, they will come to appreciate the role of the environment in contributing to disease, disorders and development, and they will be challenged to consider ethical issues of brain-behavior relationships in criminology, health care, diagnosis and treatment.

Read the original:
Neuroscience - College of Arts and Sciences - Santa Clara ...

What is Neuroscience? – allpsychologycareers.com

Rapid advances in technology combined with knowledge about how the brain and nervous system work have ushered in progress once considered purely science fiction, but today falling under a growing area of scientific study called neuroscience.

Take, for example, the case of implanting a sensor into a paralyzed individuals brain. The sensor detects thoughts that the individual has about moving an arm. These thoughts are then sent to a plug on the individuals scalp, which sends signals to a computer that translates the signals into motor movements.

Or consider the practice of placing electrodes under a persons scalp, electrodes connected to a battery-operated generator implanted under the skin near the individuals collarbone. The result? An intervention for a brain-related disorder called essential tremor.

Both of these cutting-edge medical interventions wouldnt have been possible without the field of Neuroscience, an area of specialty that wasnt formalized into its own field until 1971. Since then, the amount of investigation and research completed by those working in the field has grown faster than most other scientific areas of thought and empirical study.

And those individuals with devastating brain and spinal cord injuries, brain diseases and disorders, are the main beneficiaries of these once unimaginable scientific advancements.

The Society for Neuroscience (SfN) defines neuroscience as the study of the nervous system, including the brain, spinal cord, and networks of sensory nerve cells called neurons. It is an interdisciplinary field, meaning that it integrates several disciplines, including psychology, biology, chemistry, and physics.

In studying the nervous system, the field adds to a body of knowledge about human thought, emotion, and behavior the main area of expertise for those working in psychology, especially the field of Neuropsychology.

Both neuropsychologists and neuroscientists focus their research on the understanding of brain disorders, injuries, and deficits. For this reason, these scientists must have a solid understanding of how psychological processes relate to the brains structures and systems, or on the interrelated and inseparable connections between cognition and brain physiology.

To help those with brain disorders, neuroscientists first must understand normal brain functioning. Therefore, many neuroscientific investigations into abnormal brain functioning complement the science of normal brain functioning.

Neuroscientists study a wide range of topics related to the brain and nervous system. Most specialize, however, on a particular disability or problem associated with one brain region or area. The implanting of brain sensors is one example of specialized neuroscientific research.

In an August 2010 interview with The New York Times, John Donohue detailed how his research into combining brain signals with computers resulted in BrainGate, the invention responsible for returning some voluntary movements to paralyzed individuals. He has focused on using BrainGate to help those who have had strokes, incurred spinal cord injuries, or suffer with amyotrophic lateral sclerosis (ALS).

Donoghue, a professor of engineering and neuroscience at Brown University, told reporter Claudia Dreifus, in the article Connecting Brains to the Outside World, that when he entered graduate school in 1976, his desire was to learn how the brain works. But, he realized that that question was too broad, and he needed to break it down into a more easily studied sub-topic, which became how does the cerebral cortex allow thoughts to become action?

In the 1980s, he and colleagues from his laboratory worked on technologies that permitted them to distinguish where brain activity occurred when the body moved, such as when arms or legs moved. These technologies led to the invention of the brain sensor.

In 2004, Donoghue and other researchers implanted the sensor into an individual that had a spinal cord injury that left him paralyzed. When they turned on BrainGate the sensor attached to a scalp plug thats attached to a computer they could see activity in his brain light up when he thought about moving his left or right hand. In other words, even though his body couldnt produce the movement, his brain still processed the command.

In the NYT article, Donohue related how up until that point, many assumed that brain function was reduced or nonexistent after a debilitating spinal cord injury. But this new technology pointed out that it was the connection between the brain and the desired movement that was injured, not the brain itself. In other words, theres a break or disconnect between the brain the other parts of the nervous system.

This has profound implications not for only BrainGate, but for anyone thinking about nervous system injuries, Donohue told the NYT.

Ultimately, Donoghue said, at the goal of BrainGate is to return lives impacted by neurological injuries back to a state of normalcy, or as close as possible to the productive lives they had before the injuries or illnesses.

Neuroscientists at the Mayo Clinic also want individuals suffering with brain and neurological disorders to regain normal functioning and their livelihoods. In its quarterly publication, Sharing Mayo Clinic, Mayo describes how its research into deep brain stimulation (DBS) led to some of the first applications of this technology in the United States.

In one particular case, world-renowned violinist Roger Frisch, associate concertmaster of the Minnesota Orchestra, thought his music career would be over after being diagnosed with a condition known as essential tremor.

A progressive neurological disorder, essential tremor results in tremors during certain movements, such as eating or writing. Tremors can also occur in the head, neck, jaw, and voice.

In Frischs case, the tremors occurred in his arms while performing. Kendall Lee, M.D., Ph.D., and specialist in DBS at Mayo Clinic, believed that locating the tremors source, or area of Frischs brain where the tremors materialized, could help alleviate them.

In order to accomplish this localization, Mayos surgical team had Frisch perform in the surgical suite where a device engineered by Mayos researchers measured the exact movement of Frischs hand, tracing and mapping the movement to the area of the activated brain.

The newsletter called the device an accelerometer, a small semiconductor device that measures movement in three dimensions. It was attached to a violin bow and connected to an amplifier and radio system.

The device transmitted data to a computer monitor where the research team saw the genesis and progress of the tremor as the bow moved across the strings. Electrodes were placed on Frischs skull where the researchers located the misfiring brain signals, and the tremors stopped.

Frisch then went into surgery so that the wires could be placed under the scalp and connected to a battery-operated pulse generator that sends constant electrical pulses to the brain. The generator is implanted under the skin by the collarbone.

If you are interested in the fields of Neuropsychology and Neuroscience, in research and medical facilities designed to treat individuals suffering from brain injuries and dysfunctions, contact schools offering degrees in psychology. One career path for neuroscience professionals is to major in neuropsychology and take additional coursework in biology, physiology, anatomy, chemistry, and other sciences. A Ph.D. is required to work in most areas of neuroscience.

Diagnosing traumatic brain injury (TBI) remains a tedious and often difficult process for many healthcare professionals, especially in cases of mild or moderate TBI. As a result, some individuals dont receive treatment or intervention for possible neurological deficits.

Banyan Biomarkers, a Florida-based privately held company wants to solve that problem.

Founded by two neuroscientists, Banyans researchers are trying to identify biomarkers in blood tests that accurately predict head injury. Research by Banyans scientists and published in the journal Critical Care Medicine, stated that a 66-patient study of individuals with severe brain injury had elevated levels of UCH-LI 16 times the level of those without a head injury.

Banyans scientists also stated in another article for the European Journal of Neuroscience that laboratory studies with rats showed blood tests with increased levels of UCH-LI for those with brain injury and stroke.

Battlefield explosions and sports injuries often leave individuals dazed but seemingly fine, performing some neurological tests adequately, but actually needing medical treatment, rest and recovery.

According to the International Brain Injury Association, the Glasgow Coma Scale (GCS) is currently used to divide individuals into mild, moderate, and severe injury. This is a symptom-based neurological test, checking vital signs, heart rate, blood pressure, and the patients thinking in terms of memory and consciousness.

A blood test showing a definitive marker for brain injury would significantly increase an accurate diagnosis for those with mild and moderate head injuries.

Of the mild TBI patients 40-50% suffer persistent neurological problems from one to three months following injury, and 25% after one year, according to the International Brain Injury Association website.

Even severe cases of brain injury can be hard to recognize. In 2009, actress Natasha Richardson died from a skiing accident that injured her head. Assuring her family that she was fine, she did not receive medical treatment as quickly as her injury required.

See the original post here:
What is Neuroscience? - allpsychologycareers.com

Myriad Genetics (MYGN) versus Quotient (QTNT) Head-To-Head …

Myriad Genetics (NASDAQ: MYGN) and Quotient (NASDAQ:QTNT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Risk & Volatility

Myriad Genetics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Quotient has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

This table compares Myriad Genetics and Quotients net margins, return on equity and return on assets.

Insider & Institutional Ownership

61.5% of Quotient shares are owned by institutional investors. 6.7% of Myriad Genetics shares are owned by company insiders. Comparatively, 29.0% of Quotient shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Myriad Genetics and Quotient, as reported by MarketBeat.

Myriad Genetics currently has a consensus price target of $30.91, suggesting a potential downside of 20.48%. Quotient has a consensus price target of $11.50, suggesting a potential upside of 30.68%. Given Quotients stronger consensus rating and higher probable upside, analysts plainly believe Quotient is more favorable than Myriad Genetics.

Earnings and Valuation

This table compares Myriad Genetics and Quotients gross revenue, earnings per share and valuation.

Myriad Genetics has higher revenue and earnings than Quotient. Quotient is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Summary

Myriad Genetics beats Quotient on 8 of the 13 factors compared between the two stocks.

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It also develops, manufactures, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to donor collection agencies and testing laboratories, hospitals, independent patient testing laboratories, reference laboratories, blood banking operations, and other diagnostic companies, as well as to original equipment manufacturers. Quotient Limited was founded in 2007 and is based in Penicuik, the United Kingdom.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Continued here:
Myriad Genetics (MYGN) versus Quotient (QTNT) Head-To-Head ...

Analysts Set $4.35 Price Target for Fulgent Genetics Inc …

Fulgent Genetics Inc (NASDAQ:FLGT) has been assigned a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.

Brokers have set a 1 year consensus price objective of $4.35 for the company and are anticipating that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also given Fulgent Genetics an industry rank of 70 out of 255 based on the ratings given to related companies.

Several equities analysts have recently weighed in on FLGT shares. Credit Suisse Group decreased their price target on shares of Fulgent Genetics from $6.50 to $6.00 and set an outperform rating on the stock in a research note on Thursday, March 1st. Piper Jaffray Companies downgraded shares of Fulgent Genetics from an overweight rating to a neutral rating in a research note on Thursday, March 1st. Finally, ValuEngine raised shares of Fulgent Genetics from a sell rating to a hold rating in a research note on Wednesday, May 2nd.

Shares of Fulgent Genetics traded down $0.27, hitting $4.19, during midday trading on Friday, MarketBeat.com reports. The companys stock had a trading volume of 11,472 shares, compared to its average volume of 12,262. The company has a market cap of $79.79 million, a P/E ratio of -38.09 and a beta of 0.28. Fulgent Genetics has a 12-month low of $2.72 and a 12-month high of $7.04.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Monday, May 7th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.04) by ($0.02). The business had revenue of $4.65 million during the quarter. Fulgent Genetics had a negative return on equity of 7.62% and a negative net margin of 26.57%. analysts expect that Fulgent Genetics will post -0.29 earnings per share for the current year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

Get a free copy of the Zacks research report on Fulgent Genetics (FLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Analysts Set $4.35 Price Target for Fulgent Genetics Inc ...

Immunology | Janssen

Jennifer Jacobs

Stuyvesant Park

Jennifer is a practicing New York City artist who was diagnosed with Type 1 diabetes at the age of twelve. She refers to her art as a picture essay about this exasperating, mysterious, unpredictable, motivating, fascinating, relentless nuisance.

The rest is here:
Immunology | Janssen

Genentech: Immunology

We're constantly growing our expertise in Immunology so that we can continue to discover and develop innovative medicines for patients living with debilitating diseases, such as systemic lupus erythematosus, rheumatoid arthritis, asthma, inflammatory bowel disease, and idiopathic pulmonary fibrosis.

At Genentech our research and discovery efforts into aspects of innate and adaptive immunity are applied to the understanding and treatment of autoimmune, inflammatory and fibrotic disorders. Studying how interactions between the immune system, stromal and epithelial cells, and the environment can become dysregulated in specialized tissues underlies our strategy to develop novel therapies for the treatment of autoimmune, inflammatory, and fibrotic diseases. We rely on human patient samples and biomarker data from observational and interventional clinical trials to define the pathogenic mechanisms and mechanistically distinct patient subsets underlying unmet medical needs in complex chronic diseases.

Science Signal, April 2017

The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation

Nature, December 2015

Therapeutic antibodies reveal Notch control of transdifferentation in the adult lung

Nature, October 2015

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

Science Translational Medicine, August 2015

TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma

Nature, October 2014

Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes

Nature, February 2014

A Crohns disease variant in Atg16l1 enhances its degradation by caspase 3

Nature, February 2014

Genetics of rheumatoid arthritis contributes to biology and drug discovery

See the original post here:
Genentech: Immunology